Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.0K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.0K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

953
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
953
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

485
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
485
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

565
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
565
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

669
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
669
Inflammatory Response01:28

Inflammatory Response

16.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
16.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SOS response-induced cell division inhibitor YneA interacts with FtsW to block septal peptidoglycan synthesis in Bacillus subtilis.

The Journal of biological chemistry·2026
Same author

Investigation of in vitro antibacterial, antiglycation, and antioxidant activities of selamectin/chlorogenic acid system and their interaction with immunoglobulin G.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

Structural basis of outer membrane biogenesis and cell division by Tol/Pal nanomachinery.

Science advances·2026
Same author

Beyond text generation: large language models as autonomous agents for orchestrating synthetic biology cycles.

Bioresource technology·2026
Same author

Molecular mechanism of action of small molecule SMT-738 on bacterial lipoprotein transporter LolCDE.

Nature communications·2026
Same author

Single-Particle Nanoplastic Identification by Liquid-Liquid Interfacial Assembly for Correlative SERS-SEM/EDX.

Analytical chemistry·2026

Related Experiment Video

Updated: Jan 26, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K

ILC3 function as a double-edged sword in inflammatory bowel diseases.

Boning Zeng1,2, Shengnan Shi1, Gareth Ashworth3

  • 1Institute of Tissue Transplantation and Immunology, Department of Immunobiology, Jinan University, Guangzhou, China.

Cell Death & Disease
|April 10, 2019
PubMed
Summary

Group 3 innate lymphoid cells (ILC3) maintain gut health but can worsen inflammatory bowel diseases (IBD) when dysregulated. Understanding ILC3 function offers potential new therapies for IBD.

More Related Videos

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.7K
Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

9.1K

Related Experiment Videos

Last Updated: Jan 26, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.1K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.7K
Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

9.1K

Area of Science:

  • Immunology
  • Gastroenterology

Background:

  • Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), involve intestinal inflammation with undetermined causes.
  • Group 3 innate lymphoid cells (ILC3) are crucial for maintaining gastrointestinal mucosal homeostasis by producing cytokines like IL-22, IL-17, and GM-CSF.

Purpose of the Study:

  • To explore the role of ILC3 in the development and progression of IBD.
  • To review the biological functions of ILC3 in gut homeostasis and disease pathogenesis.
  • To discuss the therapeutic potential of targeting ILC3 in IBD treatment.

Main Methods:

  • Literature review and synthesis of current research on ILC3 and IBD.
  • Analysis of the molecular mechanisms underlying ILC3 function in physiological and pathological states.
  • Examination of cytokine profiles (IL-22, IL-17, IFN-γ) associated with ILC3 dysregulation in IBD.

Main Results:

  • ILC3 maintain gut homeostasis in healthy individuals.
  • Dysregulation of ILC3 function, including NCR+ ILC3 bias towards ILC1 and impaired regulatory ILC function, contributes to IBD pathogenesis.
  • Overexpression of IL-22, IL-17, and IFN-γ is linked to ILC3 dysfunction in IBD.

Conclusions:

  • ILC3 play a dual role in gut health and IBD, acting as key mediators in disease development.
  • Understanding ILC3 biology is essential for developing targeted therapies for IBD.
  • Modulating ILC3 activity presents a promising avenue for future IBD treatment strategies.